Hancock Jaffe Principal Investigator Dr Jorge Hernando Ulloa Presents VenoValve One Year First-In-Human Data at Charing Cross International Symposium phoenixherald.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from phoenixherald.com Daily Mail and Mail on Sunday newspapers.
Provided by Accesswire
Apr 23, 2021 4:40 PM UTC
IRVINE, CA / ACCESSWIRE / April 23, 2021 / Hancock Jaffe Laboratories, Inc. (NASDAQ:HJLI), a developer of medical devices that restore cardiac and vascular health, today announced that Dr. Jorge Hernando Ulloa, the Principal Investigator for HJLI s first-in-human VenoValve® study in Bogota, Colombia, presented one year data this past week at the Charing Cross International Symposium. The Charing Cross International Symposium is the longest-running vascular and endovascular global symposium in Europe and is attended by the world s leading experts in vascular and endovascular medicine.
Patients in the first-in-human study demonstrated significant improvement in all study endpoints including an aggregate 54% improvement in reflux (the backwards flow of blood), a 56% improvement in disease manifestations, as measured by venous clinical severity scores ( rVCSS ), and a 76% improvement in pain, as measured on a visual
Hancock Jaffe Laboratories, Inc.: Hancock Jaffe Principal Investigator Dr. Jorge Hernando Ulloa Presents VenoValve One Year First-In-Human Data at Charing Cross International Symposium April 23, 2021 /
Hancock Jaffe Laboratories, Inc. (NASDAQ:HJLI), a developer of medical devices that restore cardiac and vascular health, today announced that Dr. Jorge Hernando Ulloa, the Principal Investigator for HJLI s first-in-human VenoValve® study in Bogota, Colombia, presented one year data this past week at the Charing Cross International Symposium. The Charing Cross International Symposium is the longest-running vascular and endovascular global symposium in Europe and is attended by the world s leading experts in vascular and endovascular medicine.
Share:
IRVINE, CA / ACCESSWIRE / December 15, 2020 / Hancock Jaffe Laboratories, Inc. (NASDAQ:HJLI)(NASDAQ:HJLIW), a developer of medical devices that restore cardiac and vascular health, announced today that the final aggregated data for the VenoValve first-in-human trial shows significant improvements in all study endpoints. For the eleven patients in the first-in-human study, reflux (the backwards flow of blood) improved an average of 54%, disease manifestations as measured by a venous clinical severity scores ( VCSS ) improved 56%, and pain, as measured on a visual analog scale ( VAS ), improved 76%, all at one-year post VenoValve surgery when compared to pre-surgery levels. Safety for all patients was assessed as well at one year.
Hancock Jaffe Laboratories, Inc.: Hancock Jaffe Announces Significant Improvements in all Study Endpoints For Final VenoValve First-in-Human Data
IRVINE, CA / ACCESSWIRE / December 15, 2020 / Hancock Jaffe Laboratories, Inc. (NASDAQ:HJLI)(NASDAQ:HJLIW), a developer of medical devices that restore cardiac and vascular health, announced today that the final aggregated data for the VenoValve first-in-human trial shows significant improvements in all study endpoints. For the eleven patients in the first-in-human study, reflux (the backwards flow of blood) improved an average of 54%, disease manifestations as measured by a venous clinical severity scores ( VCSS ) improved 56%, and pain, as measured on a visual analog scale ( VAS ), improved 76%, all at one-year post VenoValve surgery when compared to pre-surgery levels. Safety for all patients was assessed as well at one year.